DDSS

[Wookie]

Oldie for me which took me in back shed for some spanking - finally turning around but playing it from the Canadian Side (DDS).

Fundamentals are finally getting there - FDA approval expected Jan 02 -2009 ( after 3 attempts) a decision on another product in July, and some goodies in the oven.


Nice little run for a few days now and seem to build to the January crescendo hopefully....

As usual do your own DD .....

http://i42.tinypic.com/28wl2m9.png
http://stockcharts.com/h-sc/ui?s=DDSS&p=D&b=5&g=5&id=p31519748722

[Albert0373]

Wow, nice run it's having!

[Wookie]

Was $0.90 when I recommended it, now riding $1.80 (a Double) less then a week later and it's not finished - watch Jan 02 - 2009 announcement. Seems rather obvious now ( or the odds are ) that the FDA will approve their outstanding formulation of a product called Tramadol.

FDA screwed around with that 3 times , missing this data, missing that , bla bla bla - expert now says FDA has no more excuse and they have to approve.

Should hit CDN $3.00 in January , and $7.00 in July if their other product is also approve - and given they are re-formulation of products already on the market odds are very good.

Can be played in the USA under DDS.

Have fun and do your DD. :santaclaus:

[Wookie]

Wow, nice run it's having!

Nice run indeed - finally - was a painful one for me for 2+Years , had too average many times...finally coming through....

Shall be a Santa after all - well for that one anyhow.

[Wookie]

Pulled back for a few days - consolidated - and now seems ready to continue its run up to the Jan 02 2009 FDA announcement.

Hopefully good news.....

Thou shall see....+ ~25% today.

[Wookie]

Well, seems the FDA wanted to wish us an Happy New Year!

Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain


Product to be Launched in the U.S. in the Second Quarter of 2009
Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that RYZOLT(TM) (tramadol HCl extended release tablets), Labopharm's once-daily formulation of the analgesic tramadol, has been approved by the U.S. Food and Drug Administration (FDA). RYZOLT is indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

"The approval of our first product in the United States is a major milestone for our Company and we look forward to our product's launch in the world's largest market for pain medications," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We believe that RYZOLT offers physicians and patients an excellent option for the treatment of pain with the benefit of once-daily dosing. We look forward to the launch of our product by our marketing partner for the U.S., Purdue Pharma."
RYZOLT is a centrally acting analgesic composed of a dual-matrix delivery system with both immediate-release and extended-release characteristics. Labopharm's marketing partner for its product in the United States, Purdue Pharma L.P., anticipates launching RYZOLT tablets in 100 mg, 200 mg and 300 mg dosage strengths in the second quarter of 2009.

The approval of RYZOLT is the first U.S. FDA approval that Labopharm has obtained for a medication using its patented Contramid(R) controlled-release technology for oral administration of solid dosage medications. Labopharm believes that its Contramid technology can be applied to a wide range of complex, small, highly water soluble molecules to control their release over a 24-hour period with a desired pharmacokinetic profile.

Pain is a potentially debilitating condition that affects an estimated 75 million Americans - more than diabetes, heart disease and cancer combined. The United States is the world's largest market for tramadol products with sales for the 12-month period ended September 2008 of more than US$650 million resulting from more than 25 million prescriptions, which have grown at a compounded annual rate of 11% over the last five corresponding periods. Labopharm believes, however, that RYZOLT will compete not only with other tramadol products, but also with other medications indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.
"In a society where people with pain are increasingly demanding simplified dosing regimens, this once-daily formulation of tramadol should be embraced by physicians and patients alike," said Nicholas J. Messina III, MD, with Vista Medical Research Inc., Mesa, AZ, who was a principal investigator in the U.S. clinical studies on RYZOLT.
Labopharm will host a conference call on Tuesday, January 6, 2009 to discuss this announcement. Additional details for the conference call will be provided via separate news release shortly.



Now turned into a 3 Bagger from my initial post here. :D

$2.10 and should be riding higher. There is another one coming in July which should hopefully bring this back to its ±$7.00 range.

I guess I can say not ALL was a fiasco in 2008...man was this a painful year.

Happy New Year to all ....:elefant::party::ciao: